CoChat

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

Open access
Halcox, Julian P., Banegas, José R., Roy, Carine, Dallongeville, Jean, De Backer, Guy, Guallar, Eliseo, Perk, Joep, Hajage, David, Henriksson, Karin M., Borghi, Claudio · 2017 · BMC Cardiovascular Disorders

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol. METHODS: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. RESULTS: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. CONCLUSIONS: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated. TRIAL REGISTRATION: The present study is registered with ClinicalTrials.gov (ID: NCT00882336).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12872-017-0591-5

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Prevalence of high TG and/or low HDL-C levels in the EURIKA population. Percentages indicated are of the total EURIKA population (N = 7641). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women Abbreviations: EURIKA European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice, HDL-C high-density lipoprotein cholesterol, TG triglyceride
Fig. 1 Prevalence of high TG and/or low HDL-C levels in the EURIKA population. Percentages indicated are of the total EURIKA population (N = 7641). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women Abbreviations: EURIKA European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice, HDL-C high-density lipoprotein cholesterol, TG triglycerideCC BY · PubMed Central
Fig. 2 Proportion of patients treated with or without statins according to markers of atherogenic dyslipidemia. Data were missing for 26 patients in the overall population, 8 patients in the high TG group, 5 patients in the low HDL-C group, and 2 patients in the high TG and low HDL-C group. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. Abbreviations: HDL-C high-density lipoprotein cholesterol, TG triglyceride
Fig. 2 Proportion of patients treated with or without statins according to markers of atherogenic dyslipidemia. Data were missing for 26 patients in the overall population, 8 patients in the high TG group, 5 patients in the low HDL-C group, and 2 patients in the high TG and low HDL-C group. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. Abbreviations: HDL-C high-density lipoprotein cholesterol, TG triglycerideCC BY · PubMed Central
Fig. 3 Proportion of patients with markers of atherogenic dyslipidemia, according to T2DM status and CVD risk. (a) Non-statin - treated patients; (b) statin-treated patients. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. aACC/AHA risk calculator [14]. bSCORE-HDL risk calculator [6, 18]. Abbreviations: ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglyceride
Fig. 3 Proportion of patients with markers of atherogenic dyslipidemia, according to T2DM status and CVD risk. (a) Non-statin - treated patients; (b) statin-treated patients. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. aACC/AHA risk calculator [14]. bSCORE-HDL risk calculator [6, 18]. Abbreviations: ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglycerideCC BY · PubMed Central
Fig. 4 Multivariate analysis of factors associated with markers of atherogenic dyslipidemia. (a) Low HDL-C levels; (b) high TG levels; (c) low HDL-C and high TG levels. p < 0.0001 for all factors. Countries of origin with an OR that was not significant have been omitted. aPer year. bRelative to male participants. cRelative to not having T2DM. dBMI ≥ 30 kg/m2, relative to not being obese. ePer mmol/l. fPer mg/l. gRelative to never smoking. hRelative to non-use. iRelative to the UK. Abbreviations: BMI body mass index, CI confidence interval, CRP C-reactive protein, HDL-C high-density lipoprotein cholesterol, OR odds ratio, T2DM type 2 diabetes mellitus, TG triglyceride
Fig. 4 Multivariate analysis of factors associated with markers of atherogenic dyslipidemia. (a) Low HDL-C levels; (b) high TG levels; (c) low HDL-C and high TG levels. p < 0.0001 for all factors. Countries of origin with an OR that was not significant have been omitted. aPer year. bRelative to male participants. cRelative to not having T2DM. dBMI ≥ 30 kg/m2, relative to not being obese. ePer mmol/l. fPer mg/l. gRelative to never smoking. hRelative to non-use. iRelative to the UK. Abbreviations: BMI body mass index, CI confidence interval, CRP C-reactive protein, HDL-C high-density lipoprotein cholesterol, OR odds ratio, T2DM type 2 diabetes mellitus, TG triglycerideCC BY · PubMed Central
Fig. 5 Association between markers of atherogenic dyslipidemia and CRP. (a) CRP levels of < 1 mg/L, 1–< 3 mg/L or ≥ 3 mg/L; (b) CRP levels < 2 mg/L or ≥ 2 mg/L. Data were missing for 76 patients in the overall population, and for 1 patient in each of the dyslipidemia groups. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. Abbreviations: CRP C-reactive protein, HDL-C high-density lipoprotein cholesterol, TG triglyceride
Fig. 5 Association between markers of atherogenic dyslipidemia and CRP. (a) CRP levels of < 1 mg/L, 1–< 3 mg/L or ≥ 3 mg/L; (b) CRP levels < 2 mg/L or ≥ 2 mg/L. Data were missing for 76 patients in the overall population, and for 1 patient in each of the dyslipidemia groups. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. Abbreviations: CRP C-reactive protein, HDL-C high-density lipoprotein cholesterol, TG triglycerideCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 122

Metadata

Authors
Halcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C.
Affiliations
  • Swansea University (GB)
  • Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
  • Inserm (FR)
  • Linnaeus University (SE)
  • Uppsala University (SE)
  • University of Bologna (IT)
Corresponding author
Halcox, Julian P.
Venue
BMC Cardiovascular Disorders
Published
2017-06-17
Volume
17
Issue
1
Pages
160-160
ISSN
1471-2261 (ISSN-L)
OpenAlex
W2626453073
Cited by
122
References
33
Citations by year
2026: 4 · 2025: 12 · 2024: 14 · 2023: 14 · 2022: 21 · 2021: 19 · 2020: 22 · 2019: 12 · 2018: 4
FWCI
10.64
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Cardiovascular Disorders (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion)
  • Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Hispana (submittedVersion)
  • Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
atherogenic dyslipidemia, hypertriglyceridemia, low HDL cholesterol, cardiovascular risk, primary prevention, lipid-lowering therapy, treatment gap, type 2 diabetes, cardiovascular risk factors
MeSH terms
Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Europe, Female, Humans, Cholesterol, HDL, Male, Middle Aged, Practice Patterns, Physicians', Primary Prevention, Risk Factors, Triglycerides, Biomarkers, Prevalence, Treatment Outcome, Practice Guidelines as Topic, Guideline Adherence, Dyslipidemias, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. https://app.cochat.ai/papers/10.1186/s12872-017-0591-5
The paper
Halcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017). Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-017-0591-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.